VasoRx is developing RNA therapies utilizing lipid nanoparticle (LNP) technology to deliver non-coding RNA specifically to the vascular endothelium, targeting chronic vascular inflammation and fibrosis. This approach aims to reverse vascular changes associated with atherosclerosis and pulmonary hypertension, conditions that can lead to severe heart and respiratory failure.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular diseases like atherosclerosis and pulmonary hypertension involve chronic vascular inflammation and fibrosis, leading to tissue damage and potentially fatal heart or respiratory failure. Current treatments often fail to reverse these underlying vascular changes.
Solution
VasoRx is developing RNA therapies that utilize a proprietary lipid nanoparticle (LNP) technology to specifically deliver non-coding RNA to the vascular endothelium. This targeted delivery aims to modulate chronic vascular inflammation, fibrosis, and vascular remodeling associated with cardiovascular diseases. By silencing or overexpressing specific genes within the vascular endothelium, VasoRx's approach seeks to reverse the vascular changes that drive disease progression. Pre-clinical studies have demonstrated the ability of VasoRx's LNP technology to silence the TGF-beta pathway in endothelium and reverse vascular changes in animal models of pulmonary hypertension and atherosclerosis.
Target Audience
The primary target audience includes patients suffering from cardiovascular diseases such as pulmonary hypertension and atherosclerotic coronary artery disease.
Features
- Unique cationic lipoprotein nanoparticles (LNP) for targeted delivery of non-coding RNA to the vascular endothelium
- Ability to deliver siRNA to mediate durable silencing of selected genes for weeks to months
- Demonstrated silencing of TGF-beta pathway in endothelium in pre-clinical studies
- Reversal of vascular changes seen in pulmonary hypertension and atherosclerosis in animal models
- LNP platform capable of transducing a high percentage of endothelial cells without inflammatory changes